ONO-4059 analog

Cat. No.:	HY-18951				
CAS No.:	1351635-67-0				
Molecular Formula:	C ₂₅ H ₂₄ N ₆ O ₃				
Molecular Weight:	456.5				
Target:	Btk; Apoptosis				
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	2 years		
		-20°C	1 year		

SOLVENT & SOLUBILITY

Pre	DMSO : 50 mg/mL (109.53 mM; Need ultrasonic)							
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg			
		1 mM	2.1906 mL	10.9529 mL	21.9058 mL			
		5 mM	0.4381 mL	2.1906 mL	4.3812 mL			
		10 mM	0.2191 mL	1.0953 mL	2.1906 mL			
	Please refer to the so	lubility information to select the app	propriate solvent.					
In Vivo		1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (5.48 mM); Clear solution; Need ultrasonic						
		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (5.48 mM); Clear solution; Need ultrasonic						
		3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (5.48 mM); Clear solution; Need ultrasonic						



CUSTOMER VALIDATION

• Science. 2017 Dec 1;358(6367):eaan4368.

NH

0

REFERENCES

[1]. Simon Rule, A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma. November 15, 2013; Blood: 122 (21)

[2]. Toshio Yoshizawa, et al. Development of a Bruton's Tyrosine Kinase (Btk) Inhibitor, ONO-4059: Efficacy in a Collagen Induced Arthritis (CIA) Model Indicates Potential Treatment for Rheumatoid Arthritis (RA). Washington, DC November 9-14, 2012.

[3]. Yamamoto, et al. Preparation of purinone derivatives as selective Btk inhibitors. From PCT Int. Appl. (2011), WO 2011152351 A1 20111208.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA